Exploratory study on predictive biomarkers for anti-HER2 drugs in breast cancer

Exploratory study on predictive biomarkers for anti-HER2 drugs in breast cancer - Predictive markers for anti-HER2 drugs

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000010797

Enrollment

Registered

2013-05-24

Start date

2012-05-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2 positive breast cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1.histologically diagnosed with invasive breast cancer,2.20 year or older, 3.IHC 3+ or HER2/CEP17>2.0 via FISH, 4. treated with lapatinib or trastuzumab, 5. archival tumor tissues available

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
To correlate the presence of somatic mutations in cancer cells and drug efficacy	—

Countries

Japan

Outcome results